Compare Plby Group Inc (PLBY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Sanofi SA — how do they compare? Plby Group Inc trades at $1.28 (market cap $143.34M), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 731.5× Plby Group Inc's market cap, and Sanofi SA pays a 5.53% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| PLBY | SNY | |
|---|---|---|
Market Cap | $143.34M | $104.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $52.34 |
52-Week Low | $1.11 | $41.33 |
Enterprise Value | $291.14M | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.23, up 5.13% today, amid a bearish technical signal. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable. Recent developments include inclusion in the Russell 2000 and 3000 indices and a major share repurchase. Analyst consensus is strongly bullish with 75% buy ratings, reflecting optimism around the company's strategic focus on licensing, media, and experiences.
The outlook for PLBY hinges on sustaining its operational turnaround and achieving profitability. Key opportunities include brand monetization and cost management, while risks involve high debt levels and competitive pressures. Investors should weigh the strong analyst support against the company's historical losses and current negative equity position.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
